In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...

Executive function—top-down processes by which the human mind controls behavior, regulating thoughts and actions—have long ...

We recently published 10 Resilient Stocks Defying Market Sentiment. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence.

We need to ban some gain-of-function research on deadly viruses. We also need a better definition of what it is we're banning.

We asked an expert to weigh in on the benefits and practicalities of functional training.